Display options
Cite
Gulbransen G, Xu W, Arroll B. Cannabidiol prescription in clinical practice: an audit on the first 400 patients in New Zealand. BJGP Open. 2020;4(1)doi: 10.3399/bjgpopen20X101010.
Gulbransen, G., Xu, W., & Arroll, B. (2020). Cannabidiol prescription in clinical practice: an audit on the first 400 patients in New Zealand. BJGP open, 4(1), . https://doi.org/10.3399/bjgpopen20X101010
Gulbransen, Graham, et al. "Cannabidiol prescription in clinical practice: an audit on the first 400 patients in New Zealand." BJGP open vol. 4,1 (2020). doi: https://doi.org/10.3399/bjgpopen20X101010
Gulbransen G, Xu W, Arroll B. Cannabidiol prescription in clinical practice: an audit on the first 400 patients in New Zealand. BJGP Open. 2020 May 01;4(1). doi: 10.3399/bjgpopen20X101010. Print 2020. PMID: 32019776; PMCID: PMC7330185.
Copy Download .nbib Format: NLM
Share it on

BJGP Open. 2020 May 01;4(1). doi: 10.3399/bjgpopen20X101010. Print 2020.

Cannabidiol prescription in clinical practice: an audit on the first 400 patients in New Zealand.

BJGP open

Graham Gulbransen, William Xu, Bruce Arroll

Affiliations

  1. Private Practitioner, Cannabis Care NZ, West Care Specialist Centre, Auckland, New Zealand [email protected].
  2. Medical Student, Department of General Practice and Primary Health Care, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
  3. Professor and Head of Department, Department of General Practice and Primary Health Care, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.

PMID: 32019776 PMCID: PMC7330185 DOI: 10.3399/bjgpopen20X101010

Abstract

BACKGROUND: Cannabidiol (CBD) is the non-euphoriant component of cannabis. In 2017, the New Zealand Misuse of Drugs Regulations (1977) were amended, allowing doctors to prescribe CBD. Therapeutic benefit and tolerability of CBD remains unclear.

AIM: To review the changes in self-reported quality of life measurements, drug tolerability, and dose-dependent relationships in patients prescribed CBD oil for various conditions at a single institution.

DESIGN & SETTING: An audit including all patients (

RESULTS: Four hundred patients were assessed for CBD and 397 received a prescription. Follow-up was completed on 253 patients (63.3%). Patients reported a mean increase of 13.6 points (

CONCLUSION: There may be analgesic and anxiolytic benefits of CBD in patients with non-cancer chronic pain and mental health conditions such as anxiety. CBD is well tolerated, making it safe to trial for non-cancer chronic pain, mental health, neurological, and cancer symptoms.

Copyright © 2020, The Authors.

Keywords: analgesics; anti-anxiety agents; cannabidiol; cannabis; chronic pain; community care; depression; mental health; patient reported outcome measures; prescribing; therapy in mental health

References

  1. J Exp Med. 2012 Jun 4;209(6):1121-34 - PubMed
  2. Neuropsychopharmacology. 2011 May;36(6):1219-26 - PubMed
  3. Pharmacol Res. 2017 Jul;121:213-218 - PubMed
  4. Cannabis Cannabinoid Res. 2017 Jun 01;2(1):139-154 - PubMed
  5. Perm J. 2019;23:18-041 - PubMed
  6. CNS Drugs. 2018 Nov;32(11):1053-1067 - PubMed
  7. N Engl J Med. 2018 May 17;378(20):1888-1897 - PubMed
  8. J Clin Epidemiol. 2008 Apr;61(4):344-9 - PubMed
  9. Neurology. 2015 Feb 24;84(8):794-802 - PubMed
  10. Br J Pharmacol. 2011 Feb;162(3):584-96 - PubMed
  11. J Pharmacol Exp Ther. 2006 Feb;316(2):780-8 - PubMed
  12. Transl Psychiatry. 2012 Mar 20;2:e94 - PubMed
  13. Brain Res. 2012 Jan 11;1431:46-52 - PubMed
  14. Health Policy. 1996 Jul;37(1):53-72 - PubMed
  15. Braz J Psychiatry. 2008 Sep;30(3):271-80 - PubMed
  16. J Psychopharmacol. 1993 Jan;7(1 Suppl):82-8 - PubMed
  17. Pain. 2019 Jan;160(1):136-150 - PubMed
  18. N Engl J Med. 2017 May 25;376(21):2011-2020 - PubMed
  19. Cochrane Database Syst Rev. 2013 Apr 30;(4):CD005175 - PubMed
  20. J Psychopharmacol. 2011 Jan;25(1):121-30 - PubMed
  21. Can Fam Physician. 2018 Feb;64(2):111-120 - PubMed
  22. Front Pharmacol. 2017 May 11;8:259 - PubMed

Publication Types